On World Liver Day today, take a moment to reflect, your daily habits speak volumes about your liver's well-being. Fatty ...

Recent advances have marked a turning point for the treatment noncirrhotic metabolic dysfunction-associated steatohepatitis (MASH), with more therapies on the horizon to hopefully better address ...

MASLD, previously called ‘fatty liver disease’, is a ticking timebomb, affecting 30 to 40 per cent of adults – most of whom don’t know they have it ...

Akero Therapeutics, 89bio, Boston Pharmaceuticals and more are working to bring novel treatment options for metabolic ...

89bio, Inc. is a clinical-stage biotech focused on liver and cardio-metabolic diseases, with its lead drug candidate ...

A recent review highlights the gaps in clinical guidelines and treatment approaches for metabolic dysfunction-associated steatohepatitis (MASH) and looks ahead to the future promise of glucagon-like ...

Over the last year, 89bio’s stock has been somewhat volatile. Shares climbed past $10 earlier this year, but dropped under $6 ...

April 15, 2025 – Inventiva (Euronext Paris and Nasdaq: IVA) (“Inventiva” or the “Company”), a clinical-stage ...

They cite previous analyses showing that 38% of adults in North America or Australia had MASLD by 2019, and that 5% had metabolic dysfunction-associated steatohepatitis (MASH), previously known as ...

A small clinical trial in China suggests that a low-dose vitamin E supplement could improve liver tissues and scarring for ...